Replies to post #111957 on Biotech Values

[masterlongevity]

Rituxan has several NHL indications in the label.

Front-line agressive
Relasped Refractory indolent
Frontline Indolent
Maintenance
Etc....


For a biosimilar, will it also need ph 3 trials in each of the NHL subindications to get approval in those area?

This is specific to Rituxan, but i have that general question about biosimilars?